Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WaveSpan-008: MK-1045 in Relapsed/Refractory FL and DLBCL
NCT07519772Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Jul 2030
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of CN201 in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co.. Started May 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07519772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519772.